These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 31087038)
1. MiR-144 overexpression as a promising therapeutic strategy to overcome glioblastoma cell invasiveness and resistance to chemotherapy. Cardoso AMS; Sousa M; Morais CM; Oancea-Castillo LR; Régnier-Vigouroux A; Rebelo O; Tão H; Barbosa M; Pedroso MCL; Jurado AS Hum Mol Genet; 2019 Aug; 28(16):2738-2751. PubMed ID: 31087038 [TBL] [Abstract][Full Text] [Related]
2. MiR-200c-based metabolic modulation in glioblastoma cells as a strategy to overcome tumor chemoresistance. Cardoso AM; Morais CM; Sousa M; Rebelo O; Tão H; Barbosa M; Pedroso de Lima MC; Jurado AS Hum Mol Genet; 2021 Nov; 30(23):2315-2331. PubMed ID: 34245265 [TBL] [Abstract][Full Text] [Related]
3. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. Stojcheva N; Schechtmann G; Sass S; Roth P; Florea AM; Stefanski A; Stühler K; Wolter M; Müller NS; Theis FJ; Weller M; Reifenberger G; Happold C Oncotarget; 2016 Mar; 7(11):12937-50. PubMed ID: 26887050 [TBL] [Abstract][Full Text] [Related]
5. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000 [TBL] [Abstract][Full Text] [Related]
6. MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis. Yang CH; Wang Y; Sims M; Cai C; He P; Yue J; Cheng J; Boop FA; Pfeffer SR; Pfeffer LM Oncotarget; 2016 Dec; 7(51):84017-84029. PubMed ID: 27705947 [TBL] [Abstract][Full Text] [Related]
7. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors. Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243 [TBL] [Abstract][Full Text] [Related]
8. Targeting BC200/miR218-5p Signaling Axis for Overcoming Temozolomide Resistance and Suppressing Glioma Stemness. Su YK; Lin JW; Shih JW; Chuang HY; Fong IH; Yeh CT; Lin CM Cells; 2020 Aug; 9(8):. PubMed ID: 32784466 [No Abstract] [Full Text] [Related]
9. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952 [TBL] [Abstract][Full Text] [Related]
10. Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance. Li WQ; Li YM; Tao BB; Lu YC; Hu GH; Liu HM; He J; Xu Y; Yu HY Med Sci Monit; 2010 Oct; 16(10):HY27-30. PubMed ID: 20885358 [TBL] [Abstract][Full Text] [Related]
11. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma. Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935 [TBL] [Abstract][Full Text] [Related]
12. High-throughput screening uncovers miRNAs enhancing glioblastoma cell susceptibility to tyrosine kinase inhibitors. Cunha PP; Costa PM; Morais CM; Lopes IR; Cardoso AM; Cardoso AL; Mano M; Jurado AS; Pedroso de Lima MC Hum Mol Genet; 2017 Nov; 26(22):4375-4387. PubMed ID: 28973155 [TBL] [Abstract][Full Text] [Related]
13. Differentiation of glioblastoma stem cells promoted by miR-128 or miR-302a overexpression enhances senescence-associated cytotoxicity of axitinib. Cardoso AM; Morais CM; Pena F; Marante T; Cunha PP; Jurado AS; Pedroso de Lima MC Hum Mol Genet; 2021 Apr; 30(3-4):160-171. PubMed ID: 33438013 [TBL] [Abstract][Full Text] [Related]
14. miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. She X; Yu Z; Cui Y; Lei Q; Wang Z; Xu G; Xiang J; Wu M; Li G Oncol Rep; 2014 Sep; 32(3):957-64. PubMed ID: 25017996 [TBL] [Abstract][Full Text] [Related]
15. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression. Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225 [TBL] [Abstract][Full Text] [Related]
16. Targeting strategies on miRNA-21 and PDCD4 for glioblastoma. Wang G; Wang JJ; Tang HM; To SS Arch Biochem Biophys; 2015 Aug; 580():64-74. PubMed ID: 26142886 [TBL] [Abstract][Full Text] [Related]
17. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide. Forte IM; Indovina P; Iannuzzi CA; Cirillo D; Di Marzo D; Barone D; Capone F; Pentimalli F; Giordano A Int J Oncol; 2019 Jun; 54(6):2189-2199. PubMed ID: 31081046 [TBL] [Abstract][Full Text] [Related]
18. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer. Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112 [TBL] [Abstract][Full Text] [Related]
19. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Li Y; Li W; Yang Y; Lu Y; He C; Hu G; Liu H; Chen J; He J; Yu H Brain Res; 2009 Aug; 1286():13-8. PubMed ID: 19559015 [TBL] [Abstract][Full Text] [Related]
20. Downregulation of long non-protein coding RNA MVIH impairs glioblastoma cell proliferation and invasion through an miR-302a-dependent mechanism. Cardoso AM; Morais CM; Rebelo O; Tão H; Barbosa M; Pedroso de Lima MC; Jurado AS Hum Mol Genet; 2021 Mar; 30(1):46-64. PubMed ID: 33438023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]